The state of clinical trials in the UK has been a central topic of discussion for some years now, but keenly so since Brexit and following the COVID-19 pandemic.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.